Table 1 Characteristics of the included studies
Study | Subjects (T/C) | Age (T/C) | Male (T/C) | Ejection fraction, (%) (T/ C) | Interventions (T/C) | Follow-up period | Outcomes | Crude events (T/C) |
|---|---|---|---|---|---|---|---|---|
O’Keefe (2007) [29] | 749/734 | 66 ± 10/66 ± 10 | 63/64 | 32 ± 6 /32 ± 6 | Eplerenone/Placebo | Mean 16 months | ①all-cause mortality | ①153/175 |
②Hyperkalaemia(>5.5 mmol/l) | ②42/22 | |||||||
③Death from CV causes | ③131/152 | |||||||
Eschalier (2013) [30] | 459/400 | 68.1 ± 7.4/N.r. | 356/N.r. | 26.44 ± 4.7/N.r. | Eplerenone/Placebo | N.r | ①Hyperkalaemia(>5.5 mmol/l) | ①63/33 |
②CV mortality+HF hospitalization | ②99/141 | |||||||
③Change in eGFR from baseline to final visit | ③- 4.94(17.4)/-2.93(18.9) | |||||||
Vadugana than (2014) [31] | 444/306 | 65.1 ± 10.1/67.9 ± 10.7 | 320/242 | 26.7 ± 7.8/28.6 ± 8.8 | MRAs/no MRAs | Mean 9.9 months | ①all-cause mortality; | ①101/98 |
②CV mortality+HF hospitalization | ②182/147 | |||||||
③Death from CV causes | ③78/66 | |||||||
Khosraviani (2014) [32] | 536/1114 | N.r. | N.r. | N.r. | Spironolactone/no spironolactone | 2 years | all-cause mortality | 79/223 |